HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Yuhsuke Ohmi Selected Research

Gangliosides

9/2022Functional validation of novel variants in B4GALNT1 associated with early-onset complex hereditary spastic paraplegia with impaired ganglioside synthesis.
12/2021Ganglioside GD2 Enhances the Malignant Phenotypes of Melanoma Cells by Cooperating with Integrins.
9/2021Lack of GD3 synthase (St8sia1) attenuates malignant properties of gliomas in genetically engineered mouse model.
3/2020Novel Molecular Mechanisms of Gangliosides in the Nervous System Elucidated by Genetic Engineering.
12/2019The ceramide moiety of disialoganglioside (GD3) is essential for GD3 recognition by the sialic acid-binding lectin SIGLEC7 on the cell surface.
4/2018Enhancement of malignant properties of human glioma cells by ganglioside GD3/GD2.
1/2018Gangliosides in Inflammation and Neurodegeneration.
1/2018Differential roles of gangliosides in malignant properties of melanomas.
10/2017Glycolipids: Essential regulator of neuro-inflammation, metabolism and gliomagenesis.
9/2016Expression of B4GALNT1, an essential glycosyltransferase for the synthesis of complex gangliosides, suppresses BACE1 degradation and modulates APP processing.
For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown:


Yuhsuke Ohmi Research Topics

Disease

14Neoplasms (Cancer)
01/2022 - 08/2010
10Inflammation (Inflammations)
03/2020 - 12/2009
9Melanoma (Melanoma, Malignant)
12/2021 - 08/2010
5Glioma (Gliomas)
09/2021 - 06/2015
4Alzheimer Disease (Alzheimer's Disease)
01/2018 - 12/2009
3Hereditary Spastic Paraplegia
09/2022 - 01/2019
3Nervous System Diseases (Neurological Disorders)
08/2020 - 01/2019
2Small Cell Lung Carcinoma (Small Cell Lung Cancer)
01/2018 - 12/2012
2Neurodegenerative Diseases (Neurodegenerative Disease)
06/2012 - 09/2011
1autosomal recessive Spastic paraplegia 26
09/2022
1Rare Diseases (Rare Disease)
09/2022
1Squamous Cell Carcinoma of Head and Neck
04/2021
1Colonic Neoplasms (Colon Cancer)
12/2019
1Neuroblastoma
04/2018
1Dementia (Dementias)
09/2016
1Arthritis (Polyarthritis)
04/2016
1Rheumatoid Arthritis
04/2016
1Experimental Arthritis
04/2016
1Neoplasm Metastasis (Metastasis)
01/2016
1Lymphoma (Lymphomas)
01/2016
1Neuroinflammatory Diseases
04/2015
1Osteosarcoma (Osteogenic Sarcoma)
12/2012
1Choroidal Neovascularization
01/2012
1Carcinogenesis
08/2011
1Ovarian Neoplasms (Ovarian Cancer)
08/2011

Drug/Important Bio-Agent (IBA)

19GangliosidesIBA
09/2022 - 09/2010
9GlycolipidsIBA
01/2022 - 12/2009
7GD3 ganglioside (GD(3))IBA
08/2021 - 08/2010
6Complement System Proteins (Complement)IBA
03/2020 - 12/2009
6GlycosphingolipidsIBA
05/2019 - 12/2012
5EnzymesIBA
12/2021 - 01/2016
5N-Acetylneuraminic Acid (Sialic Acid)IBA
12/2019 - 12/2012
4AntigensIBA
01/2022 - 08/2011
4LipidsIBA
03/2020 - 03/2011
3Complementary DNA (cDNA)IBA
12/2019 - 09/2010
2CarbohydratesIBA
01/2022 - 09/2016
2GD2 gangliosideIBA
12/2021 - 01/2018
2IntegrinsIBA
12/2021 - 08/2010
2Proto-Oncogene Proteins c-sis (Platelet Derived Growth Factor B)IBA
09/2021 - 06/2015
2CytokinesIBA
08/2021 - 12/2009
2SugarsIBA
01/2021 - 04/2016
2Biological ProductsIBA
01/2021 - 12/2012
2GlycosyltransferasesIBA
08/2020 - 01/2016
2Proteins (Proteins, Gene)FDA Link
10/2017 - 09/2016
2Focal Adhesion Protein-Tyrosine KinasesIBA
08/2016 - 12/2012
2PaxillinIBA
08/2016 - 12/2012
2AntibodiesIBA
04/2016 - 01/2016
1Neoplasm Antigens (Tumor Antigens)IBA
01/2022
1src-Family KinasesIBA
09/2021
1Matrix Metalloproteinases (MMPs)IBA
09/2021
1A-Form DNA (A-DNA)IBA
09/2021
1ChemokinesIBA
08/2021
1Nitric Oxide Synthase Type II (Inducible Nitric Oxide Synthase)IBA
08/2021
1DNA (Deoxyribonucleic Acid)IBA
08/2021
1Epidermal Growth Factor (EGF)IBA
04/2021
1Sialic AcidsIBA
01/2021
1AminoglycosidesIBA
08/2020
1Nonsense Codon (Nonsense Mutation)IBA
08/2020
1Indicators and Reagents (Reagents)IBA
08/2020
1LectinsIBA
12/2019
1LigandsIBA
12/2019
1Recombinant ProteinsIBA
12/2019
1Sialic Acid Binding Immunoglobulin-like LectinsIBA
12/2019
1Tumor Biomarkers (Tumor Markers)IBA
05/2019
1Amino Acid Transport Systems (Amino Acid Transporter)IBA
01/2018
1Peptides (Polypeptides)IBA
09/2016
1Amyloid (Amyloid Fibrils)IBA
09/2016
1Small Interfering RNA (siRNA)IBA
08/2016
1atelocollagenIBA
08/2016
1Immunoglobulin G (IgG)IBA
04/2016
1Anti-Citrullinated Protein AntibodiesIBA
04/2016
1acetyl 4-aminosalicylic acidIBA
04/2016
1Monoclonal AntibodiesIBA
01/2016
1Amyloid Precursor Protein Secretases (beta-Secretase)IBA
01/2016
1ST6GalNAc V brain-specific GD1alpha synthaseIBA
01/2016
1neogeninIBA
01/2016
1ganglioside M1b (GM1b)IBA
01/2016
1Phosphotransferases (Kinase)IBA
06/2015
1Platelet-Derived Growth Factor Receptors (Platelet-Derived Growth Factor Receptor)IBA
06/2015
1CDw17 antigen (lactosylceramide)IBA
04/2015
1Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA
01/2012
1CCN Intercellular Signaling ProteinsIBA
08/2011
1lactosylceramide 1,3- N- acetyl- beta- D- glucosaminyltransferaseIBA
08/2011

Therapy/Procedure

2Immunotherapy
01/2022 - 05/2019
1Therapeutics
05/2019